Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 122

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 122
---
 investor in a private placement offering, 322,580 Common Shares, at a purchase price of $3.10 per Common Share for aggregate gross proceeds of approximately $1 million. The initial closing of the offering closed in the amount of $500,000, with the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, resulting in an issuance of 161,290 Common Shares to the Selling Shareholder. Pursuant to the terms of the December SPA, we further issued and sold additional securities of the Company to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under a Securities Purchase Agreement entered into on October 9, 2024, or the October Debt SPA, after giving effect to the conversion price reduction of the preferred shares as a result of the Dilutive Issuances (as defined in the October Debt SPA) caused by the Company entering into the December SPA, as follows: with the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, as follows: (i) 408,871 Common Shares issuable upon the conversion of certain of the Company’s preferred participation certificates, par value CHF 0.03 per certificate, or the PPCs, pursuant to the October Debt SPA, (ii) 75,000 Common Shares issued pursuant to the October Debt SPA.

On October 9, 2024, we and certain existing warrant holders entered into warrant amendment agreements to amend those warrants issued by us to such holders, collectively, to purchase up to 105,843 Common Shares issued to such holders. The amendment makes certain adjustment to the definition of a “Fundamental Transaction” in such common warrants. In addition, we agreed to adjust the exercise price of the common warrants to CHF 0.80 and issued to such holders pre-funded warrants to purchase up to 136,648 Common Shares.

<div align='center'>II-1</div>

On October 9, 2024, we entered into the Equity Purchase Agreement, with certain accredited investors. Pursuant to the terms of the Equity Purchase Agreement, we agreed to issue and sell to the investors, in a private placement offering, (i) 806,452 Common Shares and (ii) or common warrants to purchase 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of approximately $3.2 million.

On October 9, 2024, we entered into the October